Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Equity Average (2020 - 2025)

Arcutis Biotherapeutics has reported Equity Average over the past 6 years, most recently at $173.8 million for Q4 2025.

  • Quarterly results put Equity Average at $173.8 million for Q4 2025, up 10.62% from a year ago — trailing twelve months through Dec 2025 was $173.8 million (up 10.62% YoY), and the annual figure for FY2025 was $173.5 million, up 40.95%.
  • Equity Average for Q4 2025 was $173.8 million at Arcutis Biotherapeutics, up from $148.5 million in the prior quarter.
  • Over the last five years, Equity Average for ARQT hit a ceiling of $432.7 million in Q2 2021 and a floor of $63.6 million in Q3 2023.
  • Median Equity Average over the past 5 years was $174.2 million (2023), compared with a mean of $210.3 million.
  • Biggest five-year swings in Equity Average: tumbled 72.71% in 2023 and later skyrocketed 169.65% in 2024.
  • Arcutis Biotherapeutics' Equity Average stood at $330.3 million in 2021, then dropped by 27.29% to $240.2 million in 2022, then crashed by 71.82% to $67.7 million in 2023, then surged by 132.07% to $157.1 million in 2024, then increased by 10.62% to $173.8 million in 2025.
  • The last three reported values for Equity Average were $173.8 million (Q4 2025), $148.5 million (Q3 2025), and $140.8 million (Q2 2025) per Business Quant data.